NCT01627639View on ClinicalTrials.gov

Effectiveness of Acetazolamide for Reversal of Metabolic Alkalosis in Mechanically Ventilated Chronic Obstructive Pulmonary Disease Patients

PHASE4CompletedINTERVENTIONAL

Enrollment

380

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions

Decompensated Chronic Obstructive Pulmonary Disease

Interventions

DRUG

Acetazolamide

Acetazolamide (1 g IV per day or 2 g IV per day if coprescription of loop diuretics) or Placebo (saline serum) when pure or mixed metabolic alkalosis being present until planned extubation

DRUG

Placebo

Trial Locations (1)

75015

Clinical Research Unit, European Georges Pompidou Hospital, Assistance Publique - Hôpitaux de Paris, Paris

All Listed Sponsors

collaborator

Ministry of Health, France

OTHER_GOV

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT01627639 - Effectiveness of Acetazolamide for Reversal of Metabolic Alkalosis in Mechanically Ventilated Chronic Obstructive Pulmonary Disease Patients | Biotech Hunter | Biotech Hunter